Skip to main content

View full-text article in PMC

. 2024 Jan 18;8(1):102315. doi: 10.1016/j.rpth.2024.102315

Table 4.

Results of univariate regression analysis.

Independent variable	Favorable outcomes	Spin present	Discrepancy between protocol and reported outcomes	Retrospective registration
Commercial sponsorship (SE)	-0.095 (0.60)^a	0.33 (0.7379)^a	-1.47 (0.86)^a	-0.49 (1.03)^a
OR (95% CI)	0.91 (0.28, 3.02)	1.39 (0.32, 6.00)	0.23 (0.04, 1.18)	0.62 (0.08, 5.63)
Composite outcome (SE)	0.49 (0.67)^a	0.71 (0.75)^a	1.45 (0.92)^a	1.50 (0.97)^a
OR (95% CI)	2.02 (0.45, 9.12)	2.02 (0.45, 9.12)	4.27 (0.72, 28.91)	4.50 (0.73, 37.66)
Sample size (SE)	0.00062 (0.00060)^a	-0.0018 (0.0013)^a	-0.00022 (0.00061)^a	-0.00045 (0.00074)^a
OR (95% CI)	1.00 (1.00, 1.00)	1.00 (1.00, 1.00)	1.00 (1.00, 1.00)	1.00 (1.00, 1.00)
LTFU (SE)	-0.030 (0.040)^a	0.085 (0.090)^a	-20.93 (15091.4)^a	0.0028 (0.035)^a
OR (95% CI)	0.97 (0.88, 1.04)	1.09 (0.98, 1.41)	0 (0, ∞)	1.00 (0.92, 1.08)
Year of publication (SE)	0.078 (0.048)^a	-0.050 (0.052)^a	0.032 (0.082)^a	-0.079 (0.099)^a
OR (95% CI)	1.08 (0.99, 1.20)	0.95 (0.85, 1.05)	1.03 (0.87, 1.22)	0.92 (0.76, 1.12)
Multicenter trial (SE)	-0.98 (0.62)^a	-0.81 (0.89)^a	-0.22 (0.96)^a	-0.69 (0.83)^a
OR (95% CI)	0.38 (0.11, 1.16)	0.44 (0.06, 2.27)	0.80 (0.10, 4.85)	0.50 (0.09, 2.61)
Duration of follow-up (SE)	0.00016 (0.00044)^a	-0.00035(0.0019)^a	0.0014 (0.0020)^a	0.00065 (0.00068)^a
OR (95% CI)	1.00 (1.00, 1.00)	1.00 (1.00, 1.00)	1.00 (1.00, 1.01)	1.00 (1.00, 1.00)
Primary LMWH (SE)	0.37 (1.2)^a	1.15 (1.49)^a	0.22 (1.31)^a	0.24 (1.32)^a
OR (95% CI)	1.44 (0.16, 30.81)	3.17 (0.11, 88.86)	1.25 (0.05, 15.66)	1.27 (0.10, 30.47)
Use of ITT (SE)	-0.33 (0.59)^a	1.07 (0.75)^a	-1.57 (0.93)^a	0.14 (0.74)^a
OR (95% CI)	0.72 (0.22, 2.32)	2.91 (0.67, 13.49)	0.21 (0.03, 1.13)	1.15 (0.27, 5.07)

ITT, intention-to-treat; LMWH, low-molecular-weight heparin; LTFU, loss to follow-up; OR, odds ratio.

^a

Nonsignificant P > .05.